Shots:

• The companies have submitted the sBLA for the combination therapy to expand its use as 1L treatment of unresectable- advanced/ recurrent NSCLC in Japan- for a partial change in approved items of the manufacturing and marketing approval
• The application is based on Part 1 of P-III CheckMate -227 study assessing the combination therapy vs CT in patients with CT-naïve stage IV or recurrent NSCLC whose tumors expressed PD-L1 ≥1%- resulted in improvement in OS
• Opdivo is a PD-1 immune check inhibitor harnessing the body’s own immune system to restore anti-tumor immune response while Yervoy is mAb targeting cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) thus blocking its interaction with its ligands- CD80/CD86

Click here to­ read full press release/ article 

Ref: ONO | Image: BMS